Business Wire

CA-ENCHROMA

16.7.2024 13:01:33 CEST | Business Wire | Press release

Share
EnChroma Announces Organizations Can Now Join International Color Blindness Awareness Month™ 2024

EnChroma® — creators of glasses for color blindness — today announced that organizations and businesses can now sign up to support International Color Blindness Awareness Month™ 2024. Every September, hundreds of organizations come together to promote ‘color accessibility’ and inclusion for the one in 12 men (8%) and one in 200 women (.5%) who are color blind; an estimated 13 million in the United States; 30 million in Europe; and 350 million worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716891549/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Depiction of red-green color blind and normal color vision views of colorful buildings in Amsterdam. (Photo: Business Wire)

Anytime in September, hundreds of museums, universities, businesses, libraries, schools, park systems, tourism agencies, philanthropic groups and others will make social media posts, disseminate information, and engage in other activities to educate the public about the prevalence and effects of Color Vision Deficiency (CVD).

“Awareness of just how common color blindness is and how significant its impacts are, still remains low amongst employers, educators, parents and the general public,” said Erik Ritchie, CEO of EnChroma. “From color confusion in the workplace, at school, when enjoying sports and the outdoors, or when simply doing daily activities can be frustrating for those with CVD. This year, we hope even more organizations will support International Color Blindness Awareness Month to both educate and advocate on behalf of the color blind.”

While people with normal color vision see over one million shades of color, the red-green color blind only see an estimated 10% of hues and shades. As a result, colors can appear dull, indistinct and difficult to discern; red can appear brown; green can look tan, gray or yellow; and purple and blue look similar.

Click here to see more images depicting color blindness.

Last year, over 250 organizations around the world used their voices and platforms in support including multinational corporations such as Honeywell Aerospace, Siemens Energy and Faber-Castell; renowned museums such as the Centre Pompidou and the Georgia O’Keeffe Museum; universities such as the University of North Carolina, Boston University and North Carolina State University; state and national parks such as Friends of Kauai Wildlife Refuges and Alaska State Parks; the Atlanta Botanical Garden; nature advocates like the Audubon Nature Institute; and groups such as Travel Oregon, Lions and Kiwanis clubs, and the Boy Scouts of America.

How to Apply

Organizations and businesses can sign up here to commit to making at least one social media post, or undertake any other activity, that promotes color blindness awareness in September, using any of an array of customizable images and templates. Do as little as make one social media post using a customizable template or create your own post(s) with easy-to-use tools. Participating organizations can choose to receive two pairs of EnChroma glasses to give away to color blind students, customers, staff or visitors. The offer to give away EnChroma glasses is not available to individuals.

EnChroma Color Accessibility Program™

EnChroma is the lead advocate for ‘color accessibility,’ helping more than 400 universities, K-12 schools, state and national parks, libraries, museums, tourism departments, attractions and other organizations purchase and loan EnChroma glasses to color blind students and guests. EnChroma donates a pair of glasses for each pair an organization buys to lend to the public or students. The program is also open to employers. Scenic viewers adapted for the color blind are also available and in use by park systems across 25 states.

EnChroma glasses are engineered with special optical filters that help the red-green color blind experience an expanded range of colors more vibrantly and distinctly to make schoolwork that involves color, art, nature and other experiences more ‘color accessible.’ The glasses do not deliver full color vision and results and reaction times vary. EnChroma glasses enhance color for approximately 80% of people with deuteranomalous or protanomalous red-green color blindness who have all three of their color sensing cones. Read this study by UC Davis about the glasses.

About EnChroma

Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for red-green color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with red-green color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Call 510-497-0048 or visit enchroma.com for more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716891549/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye